{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:48Z","timestamp":1790906568655,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcyt.2024.12.014","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:25:38Z","timestamp":1736166338000},"page":"516-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0092-1339","authenticated-orcid":false,"given":"Kenta","family":"Hayashino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-4732","authenticated-orcid":false,"given":"Wataru","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6728-3346","authenticated-orcid":false,"given":"Toshiki","family":"Terao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-4674","authenticated-orcid":false,"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7383-8449","authenticated-orcid":false,"given":"Chihiro","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-7913","authenticated-orcid":false,"given":"Takumi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Seike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4788-2103","authenticated-orcid":false,"given":"Daisuke","family":"Ennishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7614-2448","authenticated-orcid":false,"given":"Keiko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.12.014_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1396490","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"Ferreri","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0002","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute kidney injury after the CAR-T therapy tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large b-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0004","first-page":"e1","article-title":"Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy","volume":"200","author":"Nakamura","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0005","first-page":"129","article-title":"Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy","volume":"6","author":"Yoshida","year":"2023","journal-title":"Blood Cell Ther"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0006","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41409-023-02083-4","article-title":"Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy","volume":"58","author":"Barker","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0007","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0009","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0011","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0012","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bjh.19302","article-title":"Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: a real-world multicentre study","volume":"204","author":"Dima","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0014","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/cc9215","article-title":"Treatment of hypophosphatemia in the intensive care unit: a review","volume":"14","author":"Geerse","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0015","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/qjmed\/hcq039","article-title":"Medication-induced hypophosphatemia: a review","volume":"103","author":"Liamis","year":"2010","journal-title":"Qjm"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.ajkd.2012.03.024","article-title":"Approach to treatment of hypophosphatemia","volume":"60","author":"Felsenfeld","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0017","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0018","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1365-2796.1999.00540.x","article-title":"High prevalence of hypophosphataemia amongst patients with infectious diseases. A retrospective study","volume":"246","author":"Haglin","year":"1999","journal-title":"J Intern Med"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0002-9343(97)00275-1","article-title":"Prevalence of hypophosphatemia in sepsis and infection: the role of cytokines","volume":"104","author":"Barak","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1468786","article-title":"Hypophosphatemia in coronavirus disease 2019 (COVID-19), complications, and considerations: a systematic review","volume":"2022","author":"Fakhrolmobasheri","year":"2022","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.jcyt.2024.12.014_bib0021","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1152\/ajpendo.00474.2020","article-title":"SARS-CoV-2: influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP) metabolism and on severity of COVID-19","volume":"320","author":"van Kempen","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0022","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/MNH.0000000000000793","article-title":"Contribution of phosphate and FGF23 to CKD progression","volume":"31","author":"Jansson","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0023","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1158\/2326-6066.CIR-22-0418","article-title":"Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-targeted CAR T-cell therapy","volume":"10","author":"Tang","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0024","doi-asserted-by":"crossref","first-page":"230","DOI":"10.23736\/S0031-0808.17.03331-6","article-title":"Cardiovascular consequences of hypophosphatemia","volume":"59","author":"Ariyoshi","year":"2017","journal-title":"Panminerva Med"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0025","first-page":"573 e1- e8","article-title":"Negative prognostic impact of high-dose or long-term corticosteroid use in patients with relapsed or refractory B-cell lymphoma who received tisagenlecleucel","volume":"29","author":"Terao","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0026","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0027","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1378\/chest.107.6.1698","article-title":"Larcan A. Hemodynamic and metabolic effects of rapid correction of hypophosphatemia in patients with septic shock","volume":"107","author":"Bollaert","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.jcyt.2024.12.014_bib0028","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:43Z","timestamp":1762546183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1465324925000039"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.12.014","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hypophosphatemia following idecabtagene vicleucel regardless of the severity of cytokine release syndrome","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}